AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

14 stories found

A bright conversational knowledge pathway rises beside a closed clinical decision gate that remains in the same position.
Social good & healthJapan+3 clusters01

An HPV chatbot improved vaccine literacy without changing vaccination decisions

A randomized clinical trial in Japan found that an AI chatbot modestly improved HPV vaccine literacy compared with a standard government leaflet, but it did not measurably change caregivers' vaccination decisions after two weeks. The trial randomized 848 female caregivers of unvaccinated daughters aged 12 to 18. Its modified intention-to-treat analysis included 704 participants immediately and 477 at the two-week literacy follow-up. After adjustment, the chatbot group scored 0.30 points higher on a seven-point literacy scale at both time points. The decision result was different: 40.3 percent of assessed caregivers in the chatbot group and 39.6 percent in the leaflet group met the study's decision-to-vaccinate definition, with no statistically significant difference. The chatbot used GPT-4o with a Japan-specific library drawn from official and peer-reviewed material, stayed within a defined scope, and directed personal clinical questions to professionals. This is useful causal evidence for a narrow intervention, not proof that general-purpose chatbots improve health behavior. Attrition was substantial, participants were all female caregivers recruited online, most had college or university education, and follow-up was short. The clearest lesson is not that the chatbot failed. It is that knowledge and action are different outcomes. Scalable conversation may strengthen literacy, while trust, clinician relationships, access, and social context still determine what people do.

9 min
A weather satellite maps a cyclone, rainfall bands, wind, and solar conditions onto a high-resolution globe.
Social good & healthGlobal+2 clusters02

WeatherNext 3 pushes AI forecasting toward hourly, five-kilometer decisions

Google DeepMind says WeatherNext 3 can turn live satellite imagery and sparse station observations into higher-resolution forecasts refreshed every hour. The system produces surface temperature and moisture estimates at up to five-kilometer resolution, other surface variables at ten kilometers, and atmospheric variables at 25 kilometers. That is roughly five times sharper in key outputs than WeatherNext 2's 25-kilometer, six-hour forecasts. Google reports early-lead probabilistic precipitation improvements of up to 60 percent against IMERG satellite data, 30 percent against U.S. radar estimates, and 10 percent against rain gauges. It also says longer forecasts can be up to 50 percent more accurate, with the largest improvements in places where previous predictions were less reliable. The deployment footprint is broad: WeatherNext 3 is feeding Google Search, Gemini, Maps, Maps Platform, and Earth Engine. New energy variables include wind speed at 100 meters and measures of cloud and solar radiation that could support renewable generation planning. These are meaningful company-reported gains, not proof of equal performance everywhere. Floods, tropical cyclones, mountains, sparse-observation regions, and rare extremes remain the real test. Users should examine calibration, false alarms, lead time, regional error, and whether better scores improve decisions. Google itself directs people to national meteorological agencies for official warnings. Faster, sharper forecasts matter only when institutions can interpret them and act.

5 min
A clinician compares a paper ECG trace and a tablet, with a pencil poised to check a discrepancy.
Social good & healthGlobal+2 clusters03

A doctor in the loop is not a safety guarantee

If a hospital tells you a clinician checks the AI, that sounds reassuring. A new peer-reviewed review asks the question hidden inside that reassurance: what happens when the automated advice is wrong? Its evidence concerns the performance of the human-and-system combination, not simply whether a person was present in the workflow. The review includes 46 reports representing 41 independent cohort clusters, with 40 core cohorts. In four heterogeneous real-world computerized ECG studies, the pooled proportion of erroneous interpretations not corrected or recognized was 26.6%, with a very wide 95% confidence interval of 6.4% to 65.6%. That is not a failure rate for all clinicians, modern chatbots or clinical AI. The newer AI and language-model studies were too different to combine in the same way. Patient-level adverse events appeared in only one retrospective cohort. For a patient, the implication is neither to distrust every tool nor to assume a professional signature settles the safety question. For an institution, it is to test the actual review process using deliberately incorrect recommendations before relying on it. Does the reviewer see the underlying evidence? Can they disagree without friction? Is there enough time to check? Those are proposed design tests, not interventions this review proves will work everywhere. The study supports a harder standard for oversight: demonstrate error interception in the intended setting, then keep watching real outcomes.

4 min
A proposed slice of corporate value flows toward communities over an unfinished bridge.
Work & marketsGlobal+2 clusters04

Anthropic proposes a public-benefit stake, but the payout rules are still to come

Anthropic announced a proposed Public Benefit Fund on October 18. It says 5% of company shares would be committed to the fund, subject to stockholder approval. Additional 2% increments could be added for every 50% rise in valuation above a baseline, but those increments are at the board's discretion. Anthropic plans to house the shares in a wholly owned LLC so it can support nonprofits or make direct distributions. It says none of the equity held by that vehicle will be used for political giving or lobbying. The company points to a separate $200 million commitment to study and address labor-market effects, and says the new fund could support bolder approaches. The idea is consequential because it attaches a potential public claim to the upside of frontier AI rather than relying only on annual charity budgets. Yet it is important not to translate percentage into cash or presume a worker has been compensated. Anthropic says the fund's governance, milestones and reporting are still forthcoming. It has not specified eligibility, first disbursements, independent oversight or outcome measures. A good-faith case for flexibility exists: AI's consequences are uncertain and a rigid formula could miss them. The measurable question is whether approved equity turns into transparent support for people with real exposure. Until a public ledger appears, this is a significant proposal with unresolved delivery.

6 min
A clinician checks an AI evidence interface while weighing a treatment decision in a hospital.
Social good & healthUnited States+3 clusters05

Doctors are asking AI how to treat patients. Are we testing the right thing?

A doctor wondering which treatment to choose is a more consequential scene than an AI acing a diagnostic quiz. A new JAMA study analyzed 271 million questions submitted by 952,008 verified US clinicians to OpenEvidence between January 2024 and June 2026. Among physicians' queries, 33.1% concerned treatment and management, while 13.9% concerned diagnosis. More than half were categorized as clinical decision-making. Monthly active users rose from 355 to 703,265 over the study period, though that is growth on one platform, not a count of all US clinicians using AI. The authors say early-career physicians and nonprocedural specialties used it disproportionately. That should change the evaluation agenda. A tool can score well on diagnostic vignettes and still give weak medication guidance, omit a contraindication or misread an evolving guideline. The study did not examine the answers, clinical decisions or patient outcomes, and it could not tell whether a question was asked at the bedside or in preparation. Its topic labels came from a model, with a small clinician validation sample, and several authors disclosed employment at the platform. Those limits do not make the usage pattern unimportant; they make independent treatment-focused testing more urgent. The next studies should compare AI-assisted and usual-care decisions on real treatment tasks, measure errors as well as speed, and ask whether patients are better off. For now, the accurate headline is not that AI treats patients. It is that clinicians are increasingly asking it treatment questions before we have strong public evidence for those answers.

6 min
An empty operating room with a transparent clinical checklist faces an illuminated semiconductor fabrication plant beyond glass.
Social good & healthSouth Korea / Global+3 clusters06

AI chips are minting profit. Surgical AI still has a much thinner evidence base

Two numbers in today's sources deserve to be held side by side without pretending they belong to the same transaction. Samsung's preliminary guidance puts third-quarter operating profit at 107.4 trillion won, nearly nine times the year-earlier figure, as demand and prices for AI-related memory support earnings. These are projected company results, with a detailed divisional breakdown due later; they do not measure the social value delivered by every AI application. Separately, a peer-reviewed scoping review in npj Digital Surgery searched five databases and identified 3,020 records on intraoperative AI clinical decision support. Only five studies met its specific inclusion criteria: one completed feasibility study and four ongoing prospective studies or registries. That does not mean only five AI-in-surgery studies exist, and it does not show these systems are unsafe. It means the prospective clinical and ethical evidence under this review's narrow question remains early. The contrast is about timing and incentives. Markets can reward the infrastructure that makes AI possible long before clinical systems have demonstrated safety, equity, consent and real patient benefit under routine conditions. A chip supplier is not responsible for conducting every surgical trial, and clinical validation properly takes longer than a quarterly earnings report. Still, the scale of investment creates a public expectation: buyers and hospitals should demand prospective outcomes and override procedures before live recommendations influence care. The impressive profit is real as a company forecast. The patient benefit is a separate question that must be tested.

7 min
A doctor and patient in a clinical corridor stand near a medical device shown under ongoing monitoring.
Social good & healthUnited Kingdom+2 clusters07

The UK accepts 44 medical-AI recommendations. Now it must prove the monitoring works

The UK government has accepted all 44 recommendations from an independent commission on regulating AI in healthcare. That is a policy commitment, not 44 rules that have already taken effect or proof that an AI product improves patients' health. The most concrete change today is the opening of Phase 3 of the MHRA's AI Airlock, a regulatory sandbox focused on post-market surveillance and how AI-enabled devices behave after deployment. The commission's central critique is that one-time assessment is not enough for technology that changes, drifts or meets different patients and clinical workflows. The government promises draft guidance by December 2026 on managing changes to AI-enabled medical devices and a full implementation roadmap by spring 2027. It also plans future consultation on how devices are classified. The application terms expose an important implementation question: participation has no fee, but applicants currently fund their own studies and data access, and testing in real settings remains in a shadow pathway rather than directly informing patient decisions. That can be a sensible safety design; it may also be harder for smaller developers to finance, although participation data do not yet show exclusion. Patients should ask whether monitoring will detect unequal performance, how clinicians will report failures, who can pause an update, and whether results will be public. Healthcare AI's promise is real enough to warrant testing. The hard work starts after a policy announcement: measure outcomes over time, name the accountable institution, and show what happens when the system changes under care.

6 min
A patient reviews clear AI-prepared questions before meeting a surgeon, with an anxiety gauge and consultation timer both falling.
Social good & healthChina+4 clusters08

A local AI briefing cut pre-surgery anxiety and physician workload

A randomized phase II study offers a bounded example of medical AI that helped without pretending to replace the clinician. Researchers assigned 268 people newly diagnosed with prostate cancer and scheduled for radical prostatectomy to standard communication or an AI-assisted pathway. The intervention used a locally deployed large language model to prepare personalized answers to patient questions before the routine face-to-face discussion. Physicians remained responsible for the encounter and were blinded to group assignment. The AI-assisted group reported a mean post-communication GAD-7 anxiety score of 3.2, compared with 5.7 in the control group. Physician workload on the NASA-TLX scale averaged 39.9 versus 56.8, and routine communication time fell from 19.9 to 11.3 minutes. Satisfaction, emotions, and illness perceptions also improved. This is stronger evidence than a product testimonial, but it is not a general verdict on AI in medicine. The study was conducted at one cancer center, used a specific preoperative setting, measured near-term outcomes, and does not establish diagnostic accuracy, surgical outcomes, or long-term safety. The trial registry also still shows an earlier estimated enrollment of 160 and future completion dates, while the published paper reports 268 randomized participants; that record mismatch should be clarified. The design’s most important feature is the boundary: the model answered common questions in advance, responses were reviewed, and the surgeon still conducted the consent conversation. AI did not replace the relationship. It gave the relationship a better starting point.

10 min
A transparent lung scan and clinical evidence panel pass through several hospital environments while a performance signal changes between sites.
Social good & healthEurope+2 clusters09

Explainable AI improved oncologists’ lung-cancer predictions, but external validation exposed the limits

A multi-country study in Nature Medicine evaluated explainable AI support for treatment decisions in advanced non-small-cell lung cancer. The retrospective I3LUNG cohort included 2,396 patients treated with immunotherapy-based regimens across six centers in six countries. Models using routine clinical and blood data achieved test performance up to an area under the curve of 0.77 and outperformed traditional single biomarkers and clinical scores in the independent test set. In a separate usability study, twenty oncologists reviewed one hundred cases first without and then with model predictions and SHAP-based explanations. Sensitivity for predicting disease control increased from 0.72 to 0.87, with gains in accuracy and F1 performance; overall-survival prediction improved more modestly. The paper is valuable because it reports the limits alongside the gains. External-validation performance fell to an AUC range of 0.55 to 0.72, the complete multimodal sample was small, and added imaging, pathology, and genomic data did not produce a reliable benefit across test and external cohorts. Differences between patient populations may explain some decline, which is exactly why local calibration and prospective evaluation matter. The authors describe silent prospective validation in more than two thousand patients, another usability study, and a planned pragmatic randomized trial before deployment. The result is promising decision support, not autonomous clinical authority.

7 min
A conventional microscope with a compact motorized stage scans a bone-marrow slide and routes candidate-cell evidence to a gloved clinical reviewer.
Social good & healthUnited States and Global+3 clusters10

A low-cost self-driving microscope screens bone marrow slides for acute leukemia

A Nature Communications study presents ALLocate, a low-cost AI-powered plugin that turns a conventional microscope into a self-driving screening system for acute leukemia. The system automatically selects useful bone-marrow regions, detects cells, and produces a slide-level result without a whole-slide scanner. Researchers trained and evaluated it with more than 11,000 annotated regions and 130,000 annotated cells, then used independent multi-institutional cohorts that included 165 physical bone-marrow smear slides. Reported performance exceeded 0.99 AUROC for region selection, reached 0.90 mean average precision for cell detection, and achieved 88 percent accuracy for diagnosis on glass slides. That combination could make automated screening more accessible where scanners and specialist expertise are scarce. It does not support an autonomous final diagnosis. An 88 percent result leaves clinically important errors, and the study does not erase the need for population-specific validation, slide-quality checks, calibration, human confirmation, and escalation to a pathologist. The strongest deployment is a lower-cost bridge to expertise, not a substitute for it.

5 min
A surreal night museum scene shows a glowing digital companion separated from a human silhouette by a relationship thread, an age gate, and an easy-exit door.
Cognition & learningChina+4 clusters11

China restricts AI companions as simulated intimacy becomes a demographic concern

China's national rules for anthropomorphic AI interaction services took effect on July 15, banning virtual intimate relationships for minors and imposing safeguards on services for adults. The rules require clear notice that users are interacting with AI, periodic reminders during extended use, easy exit, protections against emotional manipulation, and intervention when dependency or addiction appears. The Guardian reports that major providers changed or removed companion features and that some users were deeply distressed when their daily relationships disappeared. Officials and researchers are also debating whether low-cost, always-available synthetic intimacy could deepen loneliness or reduce motivation for real-world relationships amid falling marriage and birth rates. That demographic link is a concern, not established causation. The stronger evidence is that AI companions can become emotionally significant and that abrupt product decisions affect vulnerable users. Effective regulation should protect minors, privacy, and exit rights without dismissing the real loneliness that makes these products attractive.

5 min
Fragments of testimony, statistics, and field reports form a luminous world map while a human hand verifies one fragile evidence thread.
Social good & healthGlobal+2 clusters12

The UN is using AI to turn fragmented rights evidence into actionable signals

UN News highlights how the United Nations is applying AI to advance human rights, including efforts to organize fragmented reports, monitoring, statistics, and open-source signals into more usable intelligence. The potential public benefit is substantial: investigators and decision-makers can identify patterns faster, connect evidence across systems, and direct attention where manual review may arrive too late. The same domain carries unusually high stakes. Rights data can expose vulnerable people, encode political gaps, or create false confidence when context is stripped away. An AI-generated signal must therefore remain a lead for accountable human investigation, not a verdict about a person, community, or state. Public-interest deployment should publish its purpose and limits, preserve source context, protect sensitive data, log how outputs are used, and provide a correction path. Speed can help human-rights work only when it strengthens evidence rather than replacing judgment.

4 min
A teen silhouette faces an AI chat window while a human support pathway and a caution signal remain visible beside it.
Social good & healthUnited States+4 clusters13

Teen AI use is common—and emotional reliance tracks higher risk

Preliminary research from The Jed Foundation surveyed more than 5,500 middle- and high-school students across 21 U.S. schools and districts between October 2025 and April 2026. Four in five had used AI; more than half used it for academics, nearly one third for relationship or problem-solving advice, more than one in ten for companionship, and nearly three in five when sad, stressed, or lonely. Students who turned to AI for emotional support, advice, difficult emotions, or companionship were also more likely to report poorer mental health, loneliness, and a history of suicidal thoughts or behaviors.

3 min
Work & marketsGlobal+2 clusters14

Blumenthal and Rosenthal, “How the Impact of Artificial Intelligence on Health Care Costs Will Be Shaped by Policy and Management Choices”

The authors argue that AI’s effect on aggregate healthcare spending will not follow automatically from technical productivity gains: payment incentives, organizational priorities, implementation capacity, and management decisions will determine whether efficiency improvements lower costs, increase service volume, or are absorbed by providers. Even organizations financially rewarded for reducing expenditures may struggle to translate AI-supported productivity into lower spending because of internal workflows, professional incentives, and institutional dynamics.

2 min